Show simple item record

DIFFERENCES IN PROGNOSIS FOR BOYS AND GIRLS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA

dc.contributor.authorSather, Harlanden_US
dc.contributor.authorMiller, Denisen_US
dc.contributor.authorNesbit, Marken_US
dc.contributor.authorHeyn, Ruth M.en_US
dc.contributor.authorHammond, Denmanen_US
dc.date.accessioned2006-04-07T18:07:10Z
dc.date.available2006-04-07T18:07:10Z
dc.date.issued1981-04-04en_US
dc.identifier.citationSather, Harland, Miller, Denis, Nesbit, Mark, Heyn, Ruth, Hammond, Denman (1981/04/04)."DIFFERENCES IN PROGNOSIS FOR BOYS AND GIRLS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA." The Lancet 317(8223): 739-743. <http://hdl.handle.net/2027.42/24400>en_US
dc.identifier.urihttp://www.sciencedirect.com/science/article/B6T1B-49MMW66-2RT/2/68d8ace32c8a20eeec263046931fe4f8en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/24400
dc.description.abstractIn the period 1968-78, 3161 children were enrolled in six studies of acute lymphoblastic leukaemia by participating institutions of the Childrens Cancer Study Group. In the first two studies, which did not include central-nervous-system (CNS) prophylaxis in the treatment programme, the outcome for male and female patients was very similar. In the following four studies, which included radiation prophylaxis to the CNS, a difference in outcome favouring females appeared consistently. This difference began about 6-12 months after initial remission and was further accentuated by withdrawal of therapy. Some of these studies also included a randomised trial of duration of therapy, studying 3 versus 5 years of maintenance treatment. Analysis of these studies suggests that sex group has implications both for duration of treatment and for optimum central-nervous-system prophylaxis.en_US
dc.format.extent667073 bytes
dc.format.extent3118 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherElsevieren_US
dc.titleDIFFERENCES IN PROGNOSIS FOR BOYS AND GIRLS WITH ACUTE LYMPHOBLASTIC LEUKAEMIAen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Pediatrics, University of Michigan, Ann Arbor, Michigan, United Statesen_US
dc.contributor.affiliationotherDepartment of Family and Preventive Medicine, University of Southern California, Los Angeles, California, U.S.A..en_US
dc.contributor.affiliationotherDepartment of Pediatrics, Memorial Sloan-Kettering Cancer Institute, New York, U.S.A.en_US
dc.contributor.affiliationotherDepartment of Pediatrics, University of Minnesota, Minneapolis, Minnesota, United Statesen_US
dc.contributor.affiliationotherChildrens Cancer Study Group, University of Southern California, Los Angeles, California, United Statesen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/24400/1/0000670.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1016/S0140-6736(81)92623-4en_US
dc.identifier.sourceThe Lanceten_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.